Feb 12, 2024, 15:36
Paolo Tarantino: Important update of the ABC trials
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Important update of the ABC trials.
With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors.
No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34).
https://ascopubs.org/doi/10.1200/JCO.23.01428 “
Source: Paolo Tarantino / X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28
Nov 13, 2024, 23:26